MARKET

ATNF

ATNF

180 Life Sciences Corp
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.590
-0.010
-0.38%
After Hours: 2.640 +0.05 +1.93% 19:55 01/21 EST
OPEN
2.620
PREV CLOSE
2.600
HIGH
2.665
LOW
2.510
VOLUME
491.61K
TURNOVER
--
52 WEEK HIGH
13.05
52 WEEK LOW
2.470
MARKET CAP
88.10M
P/E (TTM)
-2.7324
1D
5D
1M
3M
1Y
5Y
180 Life Sciences Corp. To Participate in the Biotech Showcase 2022 Virtual Conference To be Held January 10-12, 2022
PALO ALTO, Calif., Dec. 28, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory di...
GlobeNewswire · 12/28/2021 16:00
180 Life Sciences inks licensing deal with University of Oxford for liver diseases
180 Life Sciences (NASDAQ:ATNF) has entered into a new, exclusive global licensing agreement with The University of Oxford for the development and commercialization of HMGB1, a regenerative molecule for promoting
Seekingalpha · 12/15/2021 13:30
BRIEF-180 Life Sciences Says Entered Into New Licensing Agreement With University Of Oxford
reuters.com · 12/15/2021 13:20
180 Life Sciences Enters Into License Agreement With University Of Oxford For Regenerative Molecule HMGB1 For Liver Diseases; Terms Not Disclosed
180 Life Sciences Corp. (NASDAQ:ATNF) ("180 Life Sciences" or the "Company"), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory
Benzinga · 12/15/2021 13:16
Insider Buying: The 180 Life Sciences Corp. (NASDAQ:ATNF) Lead Independent Director Just Bought 328% More Shares
Investors who take an interest in 180 Life Sciences Corp. ( NASDAQ:ATNF ) should definitely note that the Lead...
Simply Wall St. · 12/12/2021 11:06
180 Life Sciences Corp (ATNF) CEO James N. Woody Bought $53,375 of Shares
CEO of 180 Life Sciences Corp (30-Year Financial, Insider Trades) James N. Woody (insider trades) bought 12,500 shares of ATNF on 12/09/2021 at an average price of $4.27 a share.
GuruFocus.com · 12/10/2021 22:15
BRIEF-180 Life Sciences Provides Follow-Up Information On Oxford University And The Company’S Successful Dupuytren’S Phase 2B Clinical Trial Results
reuters.com · 12/06/2021 14:41
180 Life Sciences Provides Follow-Up Information On Oxford University, Co's Dupuytren's Phase 2b Clinical Trial Results
180 Life Sciences Corp. (NASDAQ:ATNF) ("180 Life Sciences" or the "Company"), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory
Benzinga · 12/06/2021 13:16
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ATNF. Analyze the recent business situations of 180 Life Sciences Corp through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average ATNF stock price target is 11.00 with a high estimate of 11.00 and a low estimate of 11.00.
High11.00
Average11.00
Low11.00
Current 2.590
EPS
Actual
Estimate
-0.46-0.180.100.39
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 40
Institutional Holdings: 4.23M
% Owned: 12.43%
Shares Outstanding: 34.02M
TypeInstitutionsShares
Increased
12
1.17M
New
5
193.53K
Decreased
5
461.01K
Sold Out
6
518.60K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.82%
Pharmaceuticals & Medical Research
-1.11%
Key Executives
Co-Chairman/Executive Director
Marc Feldmann
Co-Chairman/Executive Director
Lawrence Steinman
Chief Executive Officer/Director
James Woody
Chief Financial Officer/Secretary
Ozan Pamir
Chief Operating Officer
Quan Anh Vu
Chief Scientific Officer
Jonathan Rothbard
Lead Director/Independent Director
Donald McGovern
Independent Director
Teresa DeLuca
Independent Director
Larry Gold
Independent Director
Francis Knuettel
Independent Director
Pamela Marrone
Independent Director
Russell Ray
No Data
About ATNF
180 Life Sciences Corp. is a clinical stage biotechnology company. The Company is focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation and inflammatory diseases. The Company has three product development platforms each of which focused on different diseases, pains or medical conditions and target different factors, molecules or proteins, and has their own product candidates, including Anti-TNF, which focusing on fibrosis and anti-tumour necrosis factor (anti-TNF); SCAs focused on drugs, which are synthetic cannabidiol (CBD) or cannabigerol (CBG) analogues (SCAs); and α7nAChR focusing on alpha 7 nicotinic acetylcholine receptor (α7nAChR). It conducting clinical trials only for certain indications under the anti-TNF platform. Out of its three product development platforms, only the SCAs platform, involves products that are related to CBD.

Webull offers kinds of 180 Life Sciences Corp stock information, including NASDAQ:ATNF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATNF stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ATNF stock methods without spending real money on the virtual paper trading platform.